Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing…
Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands…
Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity…
Freddie Höglund, CEO of the European Chamber of Commerce Taiwan (ECCT), and Mike Exton, Managing Director of Novartis Taiwan and Co-Chair of the Pharmaceutical Committee of the ECCT, document the…
Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing…
Petar Vazharov, Alvogen’s executive vice president for Asia Pacific, and, Jefferson Wang, general manager of Lotus, provide insights into Lotus’ tremendous evolution from a local generics company into a regional…
The Chairman & CEO of TaiGen Biotechnology discusses the growth opportunities that the company holds in China, its main target market, and documents how her long-term strategic outlook made the…
Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API…
JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The…
Fangchen Lee, Chairman of YungShin Global Holding on strengthening the groups’s vertical integration, expanding product portfolio, and instilling a collaborative approach in the local generics industry, with the vision to build a Taiwan-based pharmaceutical…
Hong-Jen Chang, former Deputy Minister of Health and current CEO and Chairman of the YFY Biotech Management Company, a Taiwan-based VC fund which has been playing an instrumental role in…
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech…
See our Cookie Privacy Policy Here